Intrinsic Therapeutics Completes First Endoscopic Barricaid Implantation in Great Lakes Region

Intrinsic Therapeutics Marks New Milestone with First Endoscopic Barricaid Implantation

On November 14, 2025, Intrinsic Therapeutics, Inc. made a remarkable announcement revealing the successful completion of the first endoscopic Barricaid implantation in the Great Lakes Region by the skilled orthopedic surgeon, Dr. Nick Nenadovich, who is affiliated with the University of Chicago. This pioneering procedure marks a significant advancement in medical technology and presents new possibilities in the treatment of patients suffering from disc herniations.

The Barricaid® Bone-Anchored Annular Closure Device is designed to address the challenges associated with recurrent disc herniations, significantly enhancing a surgeon's ability to treat these conditions effectively. Dr. Nenadovich expressed how this endoscopic method not only reduces discomfort during the procedure but also facilitates a quicker recovery for patients. He highlighted that the integration of the Barricaid implant allows for the effective management of existing disc herniations while considerably diminishing the risks of future herniations. This dual approach can greatly optimize treatment strategies and improve patient outcomes.

As endoscopic discectomies continue to rise in popularity as a preferred method for treating disc herniations, Dr. Nenadovich implemented the innovative dualPortal® endoscopic technique developed by Amplify Surgical. This approach significantly eases the learning curve for surgeons, promoting a more rapid assimilation of endoscopic methodologies into clinical practice. The combination of a discectomy followed by the placement of a Barricaid device not only lowers the chances of reherniation but also provides a more enduring relief from sciatica and other related symptoms, ultimately improving patient quality of life.

Greg Lambrecht, the Founder of Intrinsic Therapeutics, shared insights on how the Barricaid device is steering the future standards of care in surgical practices across the nation. He noted, "Surgeons nationwide are realizing the immense benefits that Barricaid brings, particularly in terms of maximizing and preserving patient outcomes following endoscopic discectomies. The incorporation of Barricaid into the surgical process for high-risk cases is becoming the new standard of care for patients undergoing discectomy surgeries."

For those interested in seeing the procedure in action, a video of Dr. Nenadovich's groundbreaking installation can be viewed on their website. The Barricaid device is not just a technological innovation; it is a potential game-changer for many who suffer from chronic back pain and the complications from disc emergencies.

The Barricaid device boasts a remarkable safety profile, having been implanted in nearly 13,000 patients and backed by various clinical studies across multiple patient demographics. These studies include two randomized controlled trials and six single-arm studies, showcasing its widespread applicability. Notable research published in JAMA, a prestigious medical journal, revealed its superior effectiveness compared to traditional discectomy over a five-year period. To further augment its application, a new Category I CPT Code 63032 for bone-anchored annular closure is set to be effective starting January 1, 2026, which will greatly assist in its adoption into surgical practice.

As the medical community eagerly anticipates the full benefits revealed by studies of Barricaid, patients and healthcare providers alike are optimistic about the future of spine surgery. Through continual breakthroughs and advancements in surgical methods, the potential to alleviate chronic pain is more attainable than ever before, marking a significant turn in the journey toward optimal care in spinal health.

While some studies related to Barricaid extend beyond FDA indications, the outcomes appear to be consistently favorable. For complete information on benefits and risks, interested parties should refer to www.Barricaid.com for more details.

Barricaid is a trademark of Intrinsic Therapeutics, Inc., and dualPortal is a registered trademark of Amplify Surgical, Inc. The CPT designation is recognized by the American Medical Association (AMA).